Form 4: AN2 Therapeutics Director Acquires 2,000 Shares in Open Market Transaction

Joseph S. Zakrzewski, a director at AN2 Therapeutics, purchased 2,000 shares of common stock at $1.40 per share on November 27, 2024.

Summary

• On November 27, 2024, Joseph S. Zakrzewski, a director of AN2 Therapeutics, Inc., acquired 2,000 shares of the company's common stock.
• The shares were purchased at a price of $1.40 per share.
• Following this transaction, Mr. Zakrzewski directly owns 125,199 shares of AN2 Therapeutics common stock.
• He also indirectly owns 405,880 shares through the Z3 Trust, for which he serves as a trustee.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it simply reports a transaction. The director's purchase could be interpreted as a positive sign, but it's not a major event.

Positives

• The director's purchase of shares could be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is relatively small in volume compared to typical institutional trading, but is still relevant as it reflects a director's personal investment decision.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates

Keywords

AN2 Therapeutics, ANTX, insider trading, stock purchase, director, Joseph S. Zakrzewski, Form 4, SEC filing